ADC Therapeutics SA
NYSE:ADCT

26.12 USD -0.3 USD ( -1.14% )

ADC Therapeutics SA (NYSE:ADCT)

Add ADCT to Watchlist

Summary

Business Profile
ADC Therapeutics SA

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. [ Read More ]

Country

Switzerland

Industry

Biotechnology

Market Cap

2.04B USD

Enterprise Value

1.72B USD

Dividend Yield

0%

Buyback Yield

-21%

Intrinsic Valuation

ADCT Intrinsic Value
Intrinsic value based on company cash flows

The intrinsic value of one ADCT stock under the base scenario is 1.1 USD. Compared to the current market price of 26.12 USD, the company's shares are overvalued by 96%.

Analyst Rating

Analyst Price Target
ADCT Price Target

12 month price targets for ADCT stock made by Wall Street analysts. The average price target is 44.71 USD with a high forecast of 57.75 USD and a low forecast of 33.33 USD.

Lowest
Forecast
33.33 USD
Upside 28%
Average
Forecast
44.71 USD
Upside 71%
Highest
Forecast
57.75 USD
Upside 121%

Competitors

Competitors Valuation Chart
ADC Therapeutics SA Competitors

Competitors Valuation Table
ADC Therapeutics SA Competitors

Shareholder Return

Stock Performance
ADCT Price Statistics

ADCT Market
1 Week +3% +1%
6 Months +12% +8%
1 Year -5% +31%
3 Years -12% +65%

Stock Price
ADCT Price Chart

1M
6M
1Y
3Y
5Y

Forecasted Financials

Revenue
Forecast of Future Revenue

-
-
-
-
-
-
-
-

Net Income
Forecast of Future Net Income

-
-
-
-
-
-
-
-

ADC Therapeutics SA Revenue and Net Income forecasts made by Wall Street analysts.